JP7837512B2 - ウイルス安定化剤、ウイルス安定化剤用ゼラチン加水分解物およびウイルス含有組成物 - Google Patents

ウイルス安定化剤、ウイルス安定化剤用ゼラチン加水分解物およびウイルス含有組成物

Info

Publication number
JP7837512B2
JP7837512B2 JP2022576995A JP2022576995A JP7837512B2 JP 7837512 B2 JP7837512 B2 JP 7837512B2 JP 2022576995 A JP2022576995 A JP 2022576995A JP 2022576995 A JP2022576995 A JP 2022576995A JP 7837512 B2 JP7837512 B2 JP 7837512B2
Authority
JP
Japan
Prior art keywords
virus
gelatin
days
stabilizer
containing composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022576995A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022158097A1 (https=
Inventor
克郎 萩原
昌孝 井田
陽介 平岡
カジ フランソワ マリ ンガコ
知希 小谷
啓司 塚本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EDUCATIONAL CORPORATION RAKUNO GAKUEN
Nitta Gelatin Inc
Original Assignee
EDUCATIONAL CORPORATION RAKUNO GAKUEN
Nitta Gelatin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EDUCATIONAL CORPORATION RAKUNO GAKUEN, Nitta Gelatin Inc filed Critical EDUCATIONAL CORPORATION RAKUNO GAKUEN
Publication of JPWO2022158097A1 publication Critical patent/JPWO2022158097A1/ja
Application granted granted Critical
Publication of JP7837512B2 publication Critical patent/JP7837512B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18621—Viruses as such, e.g. new isolates, mutants or their genomic sequences

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2022576995A 2021-01-19 2021-11-16 ウイルス安定化剤、ウイルス安定化剤用ゼラチン加水分解物およびウイルス含有組成物 Active JP7837512B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021006669 2021-01-19
JP2021006669 2021-01-19
PCT/JP2021/042018 WO2022158097A1 (ja) 2021-01-19 2021-11-16 ウイルス安定化剤、ウイルス安定化剤用ゼラチン加水分解物およびウイルス含有組成物

Publications (2)

Publication Number Publication Date
JPWO2022158097A1 JPWO2022158097A1 (https=) 2022-07-28
JP7837512B2 true JP7837512B2 (ja) 2026-03-31

Family

ID=82548688

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022576995A Active JP7837512B2 (ja) 2021-01-19 2021-11-16 ウイルス安定化剤、ウイルス安定化剤用ゼラチン加水分解物およびウイルス含有組成物

Country Status (7)

Country Link
US (1) US20230183657A1 (https=)
EP (1) EP4282955A4 (https=)
JP (1) JP7837512B2 (https=)
KR (1) KR102890748B1 (https=)
CN (1) CN115836123B (https=)
CA (1) CA3174826A1 (https=)
WO (1) WO2022158097A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117070476B (zh) * 2023-10-13 2023-12-19 金宇保灵生物药品有限公司 一株牛疱疹病毒4型毒株及其在灭活疫苗制备中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005306736A (ja) 2004-04-16 2005-11-04 Hokuyo Kk コラーゲン化粧料、その製造方法、可溶化コラーゲン繊維及びその製造装置
US20190275136A1 (en) 2016-09-19 2019-09-12 Vaxess Technologies, Inc. Vaccine formulations with increased stability
WO2020051334A1 (en) 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54140715A (en) * 1978-01-16 1979-11-01 Merck & Co Inc Vaccine stabilizer
JPS57114527A (en) * 1979-10-29 1982-07-16 Merck & Co Inc Vaccine stabilizer
US4337242A (en) * 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
CA2075521C (en) * 1992-05-05 1995-11-28 Kuniaki Koyama Stabilized live vaccine
CN1073858C (zh) * 1998-10-28 2001-10-31 浙江普康生物技术股份有限公司 含有稳定剂的甲型肝炎减毒活疫苗及制备方法
KR100294375B1 (ko) * 1998-12-29 2001-09-17 정지석 수두생바이러스백신용안정화제
EP1651272A1 (en) * 2003-08-05 2006-05-03 Fuji Photo Film B.V. Use of recombinant or synthetic gelatin as a stabiliser in vaccines
EP2769735B1 (en) 2004-10-06 2017-04-19 MedImmune, LLC Refrigerator-temperature stable influenza vaccine compositions
AP2015008733A0 (en) * 2013-03-14 2015-09-30 Takeda Vaccines Inc Compositions and methods for live, attenuated alphavirus formulations
ES2948037T3 (es) * 2014-12-18 2023-08-30 Amgen Inc Formulación estable congelada del virus del herpes simple
WO2017041083A1 (en) * 2015-09-04 2017-03-09 Inventprise, Llc Vlp stabilized vaccine compositions
WO2017056101A1 (en) * 2015-09-30 2017-04-06 Panacea Biotec Limited Stable live attenuated recombinant dengue vaccine
US10815456B2 (en) * 2016-10-04 2020-10-27 Transwell Biotech Co., Ltd. Composition, kit and method for cryopreserving cells
AU2019336940B2 (en) * 2018-09-06 2025-09-11 Bavarian Nordic A/S Storage improved poxvirus compositions
JPWO2021020446A1 (https=) * 2019-07-30 2021-02-04

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005306736A (ja) 2004-04-16 2005-11-04 Hokuyo Kk コラーゲン化粧料、その製造方法、可溶化コラーゲン繊維及びその製造装置
US20190275136A1 (en) 2016-09-19 2019-09-12 Vaxess Technologies, Inc. Vaccine formulations with increased stability
WO2020051334A1 (en) 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
JP2021536463A (ja) 2018-09-05 2021-12-27 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. デング熱ワクチン単位用量及びその投与

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
後藤 裕子、渡部 修，"カキ果実の加熱渋もどり抑制技術の開発 Developmentof Inhibitory Technique for Astringency Recurrence in Astringent Persimmon Fruit"，日本食品科学工学会誌，第57巻, 第5号，日本，社団法人日本食品科学工学会（田島 眞），2010年05月15日，pp.40-43
田村 博明 et al.，パーソナルアハンドブック Ｉ巻，日光ケミカルズ株式会社（ニッコールグループ），2016年06月07日，pp.117-118
鈴木 哲，"ゼラチンの加工食品への利用"，月刊フードケミカル，日本，株式会社 食品化学新聞社（落合 慶一郎），2007年12月01日，第23巻, 第12号，pp.58-62

Also Published As

Publication number Publication date
CN115836123B (zh) 2024-12-31
KR102890748B1 (ko) 2025-11-26
WO2022158097A1 (ja) 2022-07-28
KR20230014737A (ko) 2023-01-30
CN115836123A (zh) 2023-03-21
EP4282955A1 (en) 2023-11-29
JPWO2022158097A1 (https=) 2022-07-28
US20230183657A1 (en) 2023-06-15
EP4282955A4 (en) 2025-01-15
CA3174826A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
ES2299275T3 (es) Procedimiento y composiciones para conservar adenovirus.
ES2386457T3 (es) Composición de estabilizador químicamente definida
CN103041383B (zh) 一种活疫苗的耐热冻干保护剂、活疫苗冻干粉及其制备方法
US20100015177A1 (en) Method for Preserving Viral Particles
AU704317B2 (en) Dried blood factor composition comprising trehalose
JP2005515245A (ja) アデノウィルスの安定化された配合物
CN102892424A (zh) 病毒颗粒的稳定
WO2015059284A1 (en) A novel method for the production of stabile vaccines
EP2968112B2 (en) Stable aqueous formulations of adenovirus vectors
CN103041399A (zh) 一种耐热保护剂及其应用
JP7837512B2 (ja) ウイルス安定化剤、ウイルス安定化剤用ゼラチン加水分解物およびウイルス含有組成物
CN101052714B (zh) 稳定性和滤过性有包膜病毒制剂
WO2023023371A1 (en) Formulations containing amino acids for stabilizing lipid enveloped viral and non-viral vectors
CN115337408A (zh) 腺相关病毒制剂
JP4332694B2 (ja) 水溶性乾燥組成物
EP3127550A1 (en) Stabilizing composition for dry formulation of virus
JP2009203223A (ja) 凍結乾燥用保護剤及び生理活性物質の製造方法
JP4253688B2 (ja) 凍結乾燥用保護剤及び生理活性物質の製造方法
US20240382541A1 (en) Formulations to stabilize virus-based therapeutics
US20240382542A1 (en) Formulations to stabilize virus-based therapeutics
CN108619521A (zh) 一种动物非灭活疫苗冷冻干燥保护剂及其使用方法
BR112020021358A2 (pt) Métodos de proteção da atividade biológica de uma molécula biologicamente ativa, de uma pluralidade de moléculas de uma molécula biologicamente ativa, e, da atividade biológica de uma proteína biologicamente ativa

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260310

R150 Certificate of patent or registration of utility model

Ref document number: 7837512

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150